MiNK Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:INKT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 4.27 M2.48 M14.96 M14.24 M10.38 M Total liabilities 12.12 M13.16 M13.43 M13.03 M7.29 M Total equity -21.79 M-25.19 M-13.51 M-14.23 M-12.69 M Total liabilities & shareholders' equities 4.27 M2.48 M14.96 M14.24 M10.38 M Total debt ————— Net debt —————

News

MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

MiNK Therapeutics stock soars 80% on C-Further collaboration

MiNK Therapeutics to begin phase 1 trial of iNKT cell therapy for GvHD

Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Agilon Health (NYSE:AGL), Ambiq Micro (NYSE:AMBQ)

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

MiNK reports durable responses with iNKT cell therapy in resistant tumors

New Strong Sell Stocks for August 22nd

MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

MiNK Therapeutics Extends Cash Runway

MiNK Therapeutics Cuts Q2 Cash Use 31%